Xenetic Biosciences, Inc. Enters Into Asset Purchase Agreement With Financing Component for the Rights to Develop, Market and License Oncologic Drug Candidate Virexxa™ Nov 16, 2015
Xenetic Biosciences, Inc.'s Major Strategic Shareholders Enter Into Long Term Lock-Up Agreements Oct 7, 2015
Xenetic Biosciences Commences Third Cohort of Phase 2 Trials on Drug Candidate ErepoXen(R) for Anemia Sep 16, 2015
Xenetic Biosciences (XBIO) Contracts With Baxter International Inc Have Been Assigned to Baxalta Incorporated Following the Company Spin Out Sep 9, 2015